ClinicalTrials.Veeva

Menu

Outcomes-Based Health Program for Type 2 Diabetes

K

Kuopio University Hospital

Status

Enrolling

Conditions

Type 2 Diabetes

Treatments

Other: BitHabit digital application for behavioral lifestyle changes
Other: Onnikka weight management digital application

Study type

Interventional

Funder types

Other

Identifiers

NCT07322757
5103906

Details and patient eligibility

About

Type 2 diabetes is a growing health concern worldwide, influenced by genetic factors, overweight, metabolic syndrome, and insufficient physical activity. Good treatment and glycemic control can reduce or delay diabetes-related complications, which account for a significant and increasing share of healthcare costs in Finland. Much of this cost growth is due to complications resulting from inadequate diabetes care. Secondary prevention programs can therefore provide both health and economic benefits. Lifestyle interventions are one way to improve type 2 diabetes care and reduce complications.

This study aims to evaluate the impact of a digital lifestyle intervention combined with optimized care on treatment and outcomes among adults with type 2 diabetes at high risk for complications.

The intervention includes access to the BitHabit "Small Actions" application, which supports healthy lifestyle changes, and for participants with a body mass index (BMI) over 30, the Onnikka weight management application. The study will be conducted in North Savo, Finland, using a case-control design. Approximately 120 participants will receive the intervention and 50-100 will serve as controls. All participants will have their care plans reviewed and updated according to the Finnish Current Care Guidelines for Type 2 Diabetes. Control group participants will receive standard care, while the intervention group will receive standard care plus the digital tools. The study also includes the validation of the PAID (Problem Areas in Diabetes) questionnaire for use in Finland and in the Finnish language.

The study duration for each participant is 12 months. Data will be collected through physiological measurements, laboratory tests, questionnaires, and app usage logs. Measurements and questionnaires will be conducted at baseline and after 12 months. The analyses will describe the phenomenon, its prevalence, and associations between variables, as well as potential dependencies.

Enrollment

200 estimated patients

Sex

All

Ages

35 to 74 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Type 2 diabetes diagnosed

  • At least one of the following:

    1. diagnosed coronary artery disease,

    2. diagnosed periferal artery disease,

    3. diagnosed heart failure,

    4. diagnosed diabetic renal disease (GFR <60 OR uACR ≥ 3 for at least three months),

    5. diagnosed diabetic retinopathy,

    6. previous stroke,

    7. diagnosed atrial fibrillation or atrial flutter,

    8. age ≥ 55 years and at least two of the following conditions:

      1. smoker
      2. uses antihypertensive medication or systolic blood pressure >140 mmHg or diastolic blood pressure > 80 mmHg,
      3. uses lipid lowering medication or LDL-cholesterol > 2.6 or
      4. BMI > 25

Exclusion criteria

  • eGFR < 30
  • uACR > 200
  • BMI > 50
  • heart ejection fraction EF < 30
  • active cancer or less than five years from cancer treatment at enrollment
  • blindness in both eyes
  • severe psychotic depression
  • inability to utilize digital applications

Trial design

Primary purpose

Health Services Research

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

200 participants in 2 patient groups

Digital intervention arm
Experimental group
Description:
Digital interventions: BitHabit application and optionally Onnikka application
Treatment:
Other: Onnikka weight management digital application
Other: BitHabit digital application for behavioral lifestyle changes
Control group
No Intervention group
Description:
Control group receives same enhancement in treatment plan, but no digital interventions

Trial contacts and locations

1

Loading...

Central trial contact

Elina Pimiä, MD; Sonja Soininen, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems